Lv1
18 积分 2022-09-14 加入
Trends in the drug target landscape for autoimmune diseases
7天前
已完结
Tumour-derived small extracellular vesicles act as a barrier to therapeutic nanoparticle delivery
7天前
已关闭
Checkpoint kinase inhibitors: a patent review (2009 – 2010)
17天前
已完结
The epidemiology of inflammatory bowel disease: East meets west
1个月前
已完结
TL1A inhibition for inflammatory bowel disease treatment: From inflammation to fibrosis
1个月前
已完结
Inflammatory Bowel Disease
1个月前
已完结
AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
1个月前
已完结
Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks
2个月前
已完结
Proteasome inhibitors as anticancer agents
3个月前
已完结
POS1200 MRT-6160, A VAV1-DIRECTED MOLECULAR GLUE DEGRADER, REDUCES JOINT INFLAMMATION, CYTOKINE PRODUCTION, AND AUTOANTIBODY LEVELS IN A COLLAGEN-INDUCED ARTHRITIS DISEASE MODEL
4个月前
已关闭
皖公网安备34019202002308
